INTRODUCTION
THE APPROPRIATENESS of screening for cervical cancer should be balanced between beneficial health effects and adverse effects and costs. As the avoidance of death is the principal aim, most evaluations have concentrated on the relation between life-years Correspondence to M. van Ballegooijen. The authors are at the Department of Public Health and Social Medicine, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
saved and costs, which shows a diminishing return for the extra efforts involved in screening women more frequently [l-3] .
Although unnecessary referrals and diagnostic and local therapeutic procedures are often discussed as the major adverse effect of cervical cancer screening, reports on this effect are scarce. Treatments of advanced cancer will be reduced by early detection. But due to follow-up of false positive smears and of lesions that would have regressed spontaneously, there will be a considerable increase in the number of diagnostic and minor therapeutic procedures. We have assessed this increase and related it to the number of life-years gained. 1982-1986 and (b) in pilot region of Nijmegen in [1981] [1982] [1983] [1984] The effects of cervical cancer screening have been predicted by a mathematical model [4] [5] [6] . The model has been validated by analysing cervical cancer screening data from the British Columbia Cohort Study [7] and from pilot cervical cancer screening projects (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) in the Netherlands [8] . Both analyses led to similar conclusions [4] . Model-based analysis of the Dutch data led to the following estimates: (a) mean duration of the pre-clinical stages, 17 years and shortest at old ages; (b) regression rate of pre-invasive disease, 60% on average and highest at young ages; and (c) sensitivity of cervical cytology, 70% for cervical intraepithelial neoplasic (CIN) III. Effects were calculated compared with no early detection, which was also simulated and in which women are only detected by symptoms. In our model detection by symptoms occurs in stage IB at the earliest.
METHODS
<GIN III+ CIN III CIN IA Treatment (a) (b) (a) (b) (a)(b)
Diagnosis and treatment
Assessment of the number of women referred to a gynaecological department because of an abnormal cervical smear is of major importance when estimating the extent of diagnosis induced by screening. Referred women are supposed to undergo colposcopy at least once; most will have ectocervical biopsy and in some endocervical curettage will be done. We calculated the number of referred women from the predicted numbers of detected women. We assumed that all women with a histologically confirmed CIN III+ and 65% of the women followed up without a confirmed CIN III+ have been referred to a gynaecologist. The other 35% of the latter group is assumed to have had only repeat smears done by the general practitioner, as the data from the pilot regions indicate. In the pilot regions, a Pap-smear with moderate dysplasia was followed by a repeat smear within a few weeks. A smear with severe dysplasia or more led to immediate referral to a gynaecologist.
The difference between the two data sets stresses the variability in medical practice. Hysterectomies were more frequent in Nijmegen. The reasons for this were not investigated. Current developments towards less aggressive treatments are the further introduction of colposcopy in the assessment of suspected cervical abnormalities and the decreasing rates for hysterectomies in general (there has been a more than 30% fall in the age group 35-50 in the Netherlands since the late 1970s [9] ). Hospital departments that reported data on their treatment procedures are probably departments that follow these developments more closely than average. The percentage for less aggressive procedures in these hospitals, however, may be a good approximation for future practice. So we used the hospital data for the assumptions on the average stage-specific treatment (Table 2) .
To calculate the numbers of primary treatment procedures, a schedule has been devised with a realistic frequency of treatments by stage of disease. This schedule was applied on the predicted numbers of detected women by stage.
The possible treatment procedures in CIN and microinvasive
As no detailed data were available on treatment procedures in women with less than CIN III we based our assumptions for this group on reported information and on interviews with expert gynaecologists. Of the women followed up in whom no CIN III or invasive disease is found, 70% are women without any neoplasia and 30% are women with CIN I/II (Office of Evaluation and Registration of Cervical Cancer and ref. 10). We assumed no treatment in the first group. The percentages for conserving treatment and exconisations in the group with CIN I or CIN II are based on the assumption that about 60% of these women are treated and 40% are strictly followed up by cytology. From the treated group 30% must (at least) have exconisation because in about 30% of the women with CIN the transformation zone and/or the lesion cannot entirely be seen with colpos~~py. So the percentage of conserving treatments in the women referred with less than CIN III is assumed to be 13% (30% x (-446) (-580) *Women referred to a gynaecology department for cervical cancer assessment, in whom no CIN or only CIN I/II is found.
*Per woman during her lifetime. tBecause of exconisations as re-treatment procedure assumed in 5% of tWomen with abnormal smears in whom no CIN or only CIN I/II is women who had conserving treatment.
found. $Difference compared with no early detection.
) and the percentage of exconisations to be 6% (30% x 60% x 30% [rounded]). Moreover, 5% of the women who had conserving treatment are assumed to have exconisation as re-treatment. Table 3 for the three detection strategies. All results are presented per screening year, which means that the total outcomes and effects of screening in 1988-2015 have been divided by the number of screening years: 27 (i.e. "by year").
In the management of women with cervical cancer stage IA, at least an exconisation is assumed. In the Netherlands there is a consensus to avoid diagnosing stage IA without doing exconisation first. The two possible primary treatment procedures in invasive cervical cancer stages IB or higher are radical surgery (with or without additional radiotherapy) and radiotherapy (alone). Data were studied from the eight hospitals, the Nijmegen region and from several other Dutch studies [ 11, 121. All results were similar, and since no changes are expected in the near future, they were adopted. The difference in Table 2 in the assumptions between stage II + detected by early detection and stage II+ detected by symptoms is based on the more favourable distribution over the stages IIA, IIB, III and IV in women detected by screening compared with those detected by symptoms [ 131.
With more intensive screening a shift occurs in the detected precancers and cancers towards earlier stages. The total number of women followed-up increases significantly: from 349 (5 invitations) to 1044 (25 invitations) per million women per year, mainly due to the increase in follow-up of women with no histological abnormalities or only CIN I or CIN II. With intensification of screening from 5 to 10 invitations, 184 additional life-years are gained, while a further increase from 10 to 25 invitations adds only 134 life-years more per million women per year.
Intensifying the policy from 5 to 25 invitations per life-time causes a five-fold increase in the number of women referred (Table 4 ). This induces additional diagnostic and treatment procedures. More specifically, an increase from 5 to 25 invi-
Screening policies
We will discuss the results for three screening policies, with an increasing number of invitations for screening during a lifetime: 5, 10 and 25. More invitations implies a shorter interval between successive invitations. These intervals are 8, 5 and 2 years. The age-ranges are, respectively, 37-70,27-72 and 26-74 years. This is a broad age range that does not correspond with most current practice. All three are so-called efficient screening policies. Policies are efficient when their distribution of screenings over the ages leads to the largest number of life-years gained at a certain level of costs, or conversely to the least costs for a certain number of life-years gained. Our study on the costs of cervical cancer screening is presented elsewhere [5] . tations makes the number of conserving treatments rise from 25 to 106 and exconisations rise from 47 to 157 per million women per year. The effect on the number of hysterectomies (total plus radical) of intensifying early detection efforts is modest. The reason is that the rise in the number of total hysterectomies caused by the increase in the number of women detected with CIN III (Table  3) is neutralised by a decrease in radical hysterectomies caused by the fall in the number of women diagnosed with cervical cancer stage IB or higher. The number of primary radiotherapies falls as a result of the decrease in the number of diagnosed stages IB and higher. Tables 3 and 4 can be used to calculate the balance between the efforts and risks needed to prevent more deaths from cervical cancers by more intensive screening. With 5 invitations, for every death avoided, 2800 preventive Pap-smears, 9 referrals and 4 minor treatment procedures are needed. With 25 invitations, the corresponding figures are 7300,22 and 8.
One reason for the deteriorating balance between beneficial and adverse effects is the strongly increased detection of women with no abnormalities or with lesions which are less advanced than CIN III (Table 3 ). The second reason is the increased detection of women with CIN III that would have regressed spontaneously. According to our predictions, this number would go from 32 to 77 to 121 per million women per year when intensifying the policy from 5 to 10 to 25 invitations, respectively. The resulting additional treatments, a negative side-effect inherent to early detection of cervical cancer, do not result in avoided invasive disease or life-years gained. Adverse effects all increase at last two to three times as fast as the beneficial effects when intensifying the early detection policy (Fig. 1) .
Overall the diagnostic and treatment procedures induced by cervical cancer screening precede the mortality reduction by many years. Discounting of effects (when not considering the costs) is disputable. Nevertheless, when all effects are discounted with a rate of 5%, the ratios between unfavourable and favourable effects rise between 160% and 200%. There is not only a diminishing return for the extra efforts involved in screening women more frequently, but there is also an increasing risk for women to be referred and treated without having the benefit of invasive disease being presented.
More aggressive earb treatment
The results presented are very sensitive to the treatment procedures assumed in pre-invasive and micro-invasive stages, because of the large number of women concerned. Therefore we also made calculations for a more aggressive schedule, with a shift from minor treatment procedures to hysterectomies and less untreated women (Table 5 ). The results (Table 6) should be compared with those of Table 3 . There is a sharp increase in the number of hysterectomies: for a limited early detection policy (5 invitations), a net decrease of 2 hysterectomies has now turned into a net increase of 48. For more intensive screening policies, this number increases nearly linearly, contrary to the number of deaths avoided. This is an important finding, as intensive policies are often advocated, for instance by the National Cancer Institute [ 141.
The beneficial effects of screening are unaffected by the new assumptions, as survival is reported to remain excellent when more local treatment procedures are used in CIN and cervical cancer stage IA, provided the right selection criteria are used . The numbers and types of treatments without early detection remain unchanged, as no women with pre-invasive or micro-invasive disease are detected by symptoms in our calculations.
DISCUSSION
Complete data on treatments used in women with CIN I and CIN II are scarce. About 10% of women with CIN III in British Table 3 should be interchanged. The total level of adverse effects would be lower, but the pattern of increasing risks for women with increasingly intensive policies would remain unchanged.
many referrals for diagnosis, conserving treatment procedures, exconisations and total hysterectomies are acceptable per radical treatment or death avoided. Our aim was not to provide an absolute answer to this question, but to provide the material required to compare different policies on these criteria.
Results have been calculated for an average duration of preclinical disease of 17 years, a regression rate of 60% and a sensitivity of 70%. The calculations have been repeated for other values for duration, regression and sensitivity, which could still explain the results of screening in Canada and the Netherlands. The results were not affected substantially. In a sensitivity analysis we also studied the influence of possible changes in incidence and natural history on our results. In case of a higher cervical cancer incidence (in the absence of screening) in the future, all beneficial effects and some adverse effects increase proportionally. A smaller (or larger) number of spontaneously regressing lesions makes adverse effects decrease (or increase), leaving the number of deaths avoided unaltered.
ofMass
In efficient policies screening starts at about age 30. It is often advocated to start screening younger, perhaps around age 20 [ 14, 181. Indeed, present screening by general practitioners and gynaecologists concentrates between the ages 20 and 35. Our calculations indicate that such early detection policies lead to many more diagnostic and treatment procedures per death avoided. For instance a screening policy that invites women every year between the age of 20 and 35, and every 5 years between 35 and 60 [18] has the following effects. Per death avoided, 11800 smears, 37 referrals and 16 minor treatment procedures are needed. The number of deaths avoided, however, is only 17 per million women per screening year. We found that the ratio between beneficial and adverse effects is dramatically unfavourable compared with those from efficient policies. This is mainly caused by the regression rate of CIN III being especially high in young women and, if screening starts from age 30 or 35, most of the women with progressive CIN III at early age still detected in this pre-invasive stage, the mean duration of progressive CIN III being about 15 years.
